Pablo Legorreta, Royalty Pharma CEO (Patrick T. Fallon/Bloomberg via Getty Images)

Roy­al­ty Phar­ma ex­ecs shed light on strat­e­gy be­hind their first gene ther­a­py deal

A deal with Fer­ring Phar­ma­ceu­ti­cals last month rep­re­sent­ed Roy­al­ty Phar­ma’s first for­ay in­to gene ther­a­py roy­al­ties, and it’s al­ready rais­ing ques­tions about whether it rep­re­sents a shift in the com­pa­ny’s phi­los­o­phy.

CEO Pablo Legor­re­ta and oth­er Roy­al­ty ex­ecs ad­dressed the top­ic for the first time Tues­day at Mor­gan Stan­ley’s health­care con­fer­ence in New York. While they’re ex­cit­ed about the Fer­ring deal, they sug­gest­ed that much of the strat­e­gy that’s guid­ed Roy­al­ty for its near­ly three-decade ex­is­tence will re­main the same.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.